Upgraded estimate of addressable market for Mangoral to $500-600 million annually
Ascelia Pharma AB (publ) (ticker: ACE) today announced that its estimate of the addressable market in the US, EU and Japan for its lead candidate drug Mangoral has been increased to $500-600 million (previously $350-500 million). Preparations for launch are progressing well, with a strong case for own commercialization in the US. Investors, analysts and media are invited to today’s virtual Capital Markets Day where Mangoral’s market opportunity and commercial preparations are in focus.Upgraded estimate of addressable market The addressable market for Ascelia Pharma’s novel contrast agent